Evidence map›Paper›PMID 42004050›Full record

ArticleDevelopment & reproduction2026

Characteristics of the Stem Cell Intellectual Property Rights and Patent Status: Focusing on Papers and Clinical Trials.

Gi Jin Kim, YoungJun Kim, Wang-Jae Shin, Younggwan Jeon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Development & reproduction, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gi Jin KimGraduate School of Management of Technology, Korea University, Seoul 02841, Korea.ORCID https://orcid.org/0000-0002-2320-7157
YoungJun KimGraduate School of Management of Technology, Korea University, Seoul 02841, Korea.ORCID https://orcid.org/0000-0002-5106-7016
Wang-Jae ShinDepartment of Business Administration, College of Economics & Business Administration, Cheongju University, Cheongju 28503, Korea.ORCID https://orcid.org/0009-0004-6923-0215
Younggwan JeonJNP Intellectual Property and Law, Seoul 05855, Korea.ORCID https://orcid.org/0009-0006-1630-9688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the field of regenerative medicine, stem cell therapeutic development has emerged as a key technological area. Since the establishment and characterization of human embryonic stem cell lines by James Thomson in 1998, stem cell research has expanded rapidly, accelerating industrialization through the strategic protection of intellectual property (IP) rights. As technological specialization and clinical trial expansion have progressed-particularly since 2015-the feasibility of commercialization has increased. However, IP analyses in the stem cell field have largely been limited to fragmented patent trend studies. This study analyzed the characteristics and limitations of stem cell-based IP and examined the correlations among scientific publications, patent activity, and clinical trials by stem cell type from 2000 to 2020. The findings revealed significant differences among stem cell categories. In particular, adult stem cells (ASCs) demonstrated strong positive correlations between patent filings and SCI-indexed publications (R

Indexed as

Adult stem cellClinical trialsIntellectual propertyRegenerative medicineTherapeutics

Identifiers

PMID42004050
PMCPMC13086561

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.